GlassScriptPhysician profile
Kimberly Kleiss
NPI 1447290697
$1,992.25
in general payments reported to CMS, 2019-2025
32 companies · $459 in 2025
The $459 reported for 2025 was more than what 77% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $369 · 2020: $49.81 · 2021: $258 · 2022: $256 · 2023: $322 · 2024: $278 · 2025: $459.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,060.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,059.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $281.78 | 2019-2025 | |
| Abbvie INC. | $240.79 | 2019-2023 | |
| Astellas Pharma US INC | $172.95 | 2023-2025 | Veozah, Myrbetriq |
| Hologic Sales and Service, LLC | $151.29 | 2020-2025 | Aptima, Thinprep 2000 Processor |
| Minerva Surgical, INC | $143.91 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $131.45 | 2019-2025 | |
| Biogen, INC. | $106.15 | 2024-2025 | Zurzuvae |
| Mayne Pharma Commercial LLC | $88.24 | 2021-2025 | |
| Coopersurgical, INC. | $66.54 | 2019-2023 | Paragard T 380a |
| Therapeuticsmd, INC. | $61.85 | 2019-2022 | |
| Organon LLC | $59.89 | 2022-2024 | Nexplanon |
| Sage Therapeutics, LLC | $52.81 | 2024 | |
| Lilly USA, LLC | $40.83 | 2025 | Zepbound, Mounjaro |
| Merck Sharp & Dohme LLC | $31.50 | 2019-2023 | Gardasil 9 |
| Optumhealth Care Solutions, LLC | $30.20 | 2025 | Eitan Medical, Vivify Health Care Team Portal 001 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Embecta Corp. | $27.07 | 2024 | |
| Medtronic, INC. | $26.58 | 2022 | |
| Dexcom, INC. | $26.49 | 2023 | Dexcom G6 Transmitter |
| Meditrina | $26.21 | 2019-2024 | |
| Convatec INC. | $25.59 | 2023 | |
| Millicent US INC | $24.32 | 2025 | Intrarosa |
| Roche Diagnostics Corporation | $21.14 | 2019 | |
| Abbott Laboratories | $21.01 | 2023 | Freestyle Libre 3 |
| Evofem Biosciences, INC. | $19.71 | 2021 | |
| Hologic INC | $17.94 | 2021 | |
| Smith+Nephew, INC. | $16.02 | 2025 | Pico 14 |
| Mylan Pharmaceuticals INC. | $15.27 | 2021 | |
| Vertical Pharmaceuticals, LLC | $13.83 | 2019 | |
| Amag Pharmaceuticals, INC. | $13.35 | 2019 | |
| Becton, Dickinson and Company | $12.81 | 2019 | |
| Duchesnay USA Incorporated | $12.47 | 2019 | |
| Gilead Sciences, INC. | $12.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kimberly Kleiss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.